Research Archives - Page 13 Of 17

‘Exhausting’ and ‘energizing’: First leader of high-risk medical research agency discusses startup | Science

Nine months after it was made by Congress, President Joe Biden’s new company for substantial-danger biomedical research has begun to choose condition below its first chief, Renee Wegrzyn. The 45-calendar year-old used biologist is a veteran of the Protection Sophisticated Investigation Jobs Company (DARPA), the product for the new company that, for now, is component of the National Institutes of Wellbeing (NIH).

Wegrzyn, who started out as director of the Sophisticated Research Jobs Company for Overall health (ARPA-H) on 11 October, has given that quintupled the agency’s employees, launched a web-site and Twitter account, and started to meet with the several analysis leaders, legislators, and patient advocates who pushed to build the agency and disagreed in excess of irrespective of whether it must be impartial of NIH.

ARPA-H has also rolled out 4 “mission focus areas.” They are: developing resources and platforms that reduce throughout ailments, overcoming geographic and manufacturing problems that hold solutions from reaching clients, crafting preventative health and fitness packages, and building resilient wellness care devices that can deal with crises this sort of as pandemics and local climate adjust.

As with DARPA, the coronary heart of the new company will be its highly effective program supervisors. Every single will get $50 million to $150 million to spend on projects they will find, without the need of the rigid oversight of peer-critique panels. Wegrzyn expects to use up to 20 application administrators by the finish of 2023 to start out paying out the $1 billion Congress gave ARPA-H to get began.

Wegrzyn says her major priority right now is using the services of these application managers. In their apps, they must pitch two suggestions and solution some concerns formulated by former DARPA Director George Heilmeier, this kind of as: What are you hoping to do? What is new? Who cares? (The concerns are recognized as the Heilmeier Catechism.)

Whilst the agency does not still know the place its headquarters will be—some say it really should be considerably from the NIH campus in Bethesda, Maryland—Wegrzyn states software administrators will not have to relocate and can do the job remotely.

Yesterday, Wegrzyn spoke with ScienceInsider about her ideas. This conversation has been lightly edited for brevity and clarity.

Q: What are you looking for in the application supervisors?

A: What’s key is that we have a assorted staff not only in demographics, but the subject areas that they function on. There’s a ton of scope for health, from molecular abilities all the way to surgeons. But also varied geographies are essential to us. And various experiences—government, field, academia. And they should really be hazard takers and very good collaborators.

Q: Are you having a lot of apps?

A: Yes, it is been fairly exciting to see the diversity of responses. Not everyone has observed the Heilmeier questions before. We’re supporting coach some of the folks. How do you formulate your principles, make positive that they are quantitative? And why ARPA-H? There’s so a lot of other funding organizations out there, we will need to actually swiftly household in on options that are quite special for our agency.

Q: You anticipate to collaborate with NIH on ideas. How will you keep away from getting just one more NIH institute?

A: When I was at the DARPA organic sciences workplace, I labored with NIH all the time due to the fact I experienced a professional medical countermeasures software. All govt stakeholders enable their other governing administration partners.

NIH is there to explain to us about the science. Would this remove a blocker in your area? And to really make certain that they are stakeholders in our program simply because we will also probably changeover thriving applications to them.

What is significant is that the method manager will be the conclusion-maker on whether or not or not to fund a little something mainly because they will presume the possibility.

Q: You’ve claimed it could get 5 to 15 many years for ARPA-H to have effects. So how are you likely to convince Congress to improve your spending budget?

A: We have to have several examples of courses exactly where you can say, “I get it, there is no other dwelling for that.” Since the goals are so bold, no matter whether it is the magnitude or the timeline.

We also want to exhibit that we have a lifestyle exactly where there’s an knowledge that you will fail, and you ought to study from individuals failures and move on very speedily. Right up until we have wins, that will be the way that we exhibit our worth.

Q: You’ve already experienced 30 meetings with members of Congress and satisfied with 10 individual illness teams. It appears like you’re getting pulled in a lot of directions.

A: There’s a ton of electricity and exhilaration. … People today want us to be successful. Patient communities all want us to share the hyperlink to the program manager software with the analysis communities that treatment about their conditions.

It is exhausting to check out to build a government company, I will be the initial to say that. But it is extremely energizing.

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

SAN RAFAEL, Calif. & BARCELONA, December 07, 2022–(Small business WIRE)–IMIDomics, Inc., a biotechnology organization concentrated on the discovery and development of new medications for the cure of patients with immune-mediated inflammatory diseases (IMIDs), announced now the development of an Immunology Advisory Board consisting of a range of scientific and field luminaries with working experience in building and bringing to marketplace new therapies focusing on IMIDs.

“As we proceed to refine our Precision Discovery Engine, transfer ahead with determining and pursuing targets for likely new remedies and forge critical partnership inside of the pharmaceutical and biotechnology room, owning this seasoned, respected and passionate group of advisors will be key to ensuring we’re maximizing the potential of IMIDomics to provide meaningful effects for IMID clients,” claimed Fred Craves, CEO of IMIDomics. “We are honored and thrilled to get the job done intently with just about every of them and tap their unparalleled knowledge.”

Customers of the IMIDomics Immunology Advisory Board consist of:

André Veillette, M.D.: Dr. Veillette is a earth-recognized immunologist and medical oncologist who, over the earlier 3 many years, has finished revolutionary get the job done on figuring out and characterizing intracellular molecules and receptors that participate in important roles in typical immune regulation. Dr. Veillete is a member of the COVID-19 Vaccine Activity Force and the Very long COVID Undertaking Force of the Federal government of Canada.

Arthur Weiss, M.D., Ph.D.: Dr. Weiss is the Ephraim P. Engleman Distinguished Professor of Rheumatology at the College of California San Francisco the place he has been on school considering the fact that 1985. From 1988 via 2011, he served as Main of Rheumatology at UCSF. Dr. Weiss scientific tests signal transduction in the immune method, concentrating on the roles of tyrosine kinases and phosphatases in regulating lymphocyte activation and how abnormalities in tyrosine phosphorylation pathways lead to immunologically mediated conditions.

Dan Littman, M.D., Ph.D.: Dr. Littman, is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the New York University School of Medicine and an investigator of the Howard Hughes Medical lnstitute. Dr. Littman investigates how microbiota and their solutions impact host immune responses, contributing to homeostasis or inflammatory illness. He serves on various educational and business advisory boards and the Pfizer Board of Administrators.

Lewis Lanier, Ph.D.: Dr. Lanier is an American Most cancers Culture Professor, and J. Michael Bishop, MD, Distinguished Professor and Chairman of Microbiology and Immunology at the University of California San Francisco, and Director of the Parker Institute for Cancer Immunotherapy. His research group research Pure Killer cells, which recognize and reduce cells that have become transformed or contaminated by viruses. He has served as President of the American Association of Immunologists and is a member of the Countrywide Academy of Sciences.

Pablo Engel, M.D., Ph.D.: Dr. Engel is a Professor of Immunology and Head of the Immunology Device in the Office of Biomedical Sciences at the College of Barcelona. His analysis is focused on lymphocyte mobile-surface molecules and their role in the regulation of immune responses. In addition to his research, Pablo has been Secretary Basic of the European Federation of Immunological Societies (EFIS).

ABOUT IMIDOMICS, INC.

IMIDomics, Inc. is a privately held international biotechnology corporation focused on the discovery and growth of new medicines for the therapy of immune-mediated inflammatory health conditions (IMIDs). Using an exclusive industrial license with the Vall d’Hebron Clinic IMID Biobank’s to accessibility anonymized details from extra than 17,000 patients across 150 wellness facilities, IMIDomics specializes in producing exclusive insights into IMID client encounters, situations and underlying disease mechanisms. This facts sorts the foundation of the IMIDomics Precision Discovery™ Engine which leverages point out-of-the-art analytics, machine understanding and bioinformatics abilities to uncover new insights about IMIDs primarily based on precisely outlined patient populations. These insights are enabling new discoveries for remedies, diagnostics and other innovations created to deal with the unmet requires of folks living with these complex and tough ailments.

IMIDomics was established in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Office at the Vall d’Hebron University Clinic, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology. Current investors in IMIDomics include DNS Funds, Tao Capital, The Pritzker Organization, Evotec and Bristol Myers Squibb. To learn more about IMIDomics, make sure you go to www.imidomics.com.

Perspective source edition on businesswire.com: https://www.businesswire.com/news/house/20221207005088/en/

Contacts

IMIDomics Press Get hold of:
Casey Blickenstaff at Genuine Chemistry
cblickenstaff@realchemistry.com

Biden Signs Medical Marijuana Research Bill

Near up of fingers of experts dropping cannabis oil for experimentation and study. CBD oil … [+] study

getty

President Joe Biden turns the Healthcare Cannabis Research Bill into legislation, modifying how American experts can do investigate on marijuana.

As predicted by Marijuana Second final week, the White House announced on Friday that President Biden signed the Health-related Cannabis and Cannabidiol Study Enlargement Act, “which establishes a new registration approach for conducting investigation on cannabis and for production cannabis solutions for analysis functions and drug development.”

The bipartisan invoice was launched in July, rapidly passed in the House in the very same thirty day period, and unanimously accredited by the Senate in November.

Rep. Earl Blumenauer (Democrat), who sponsored the bill, unveiled a joint press assertion together with Cannabis Caucus Co-Chairs Barbara Lee (Democrat), Dave Joyce (Republican), and Brian Mast (Republican) stressing the importance of this kind of achievement.

“For decades, the federal government has stood in the way of science and progress—peddling a misguided and discriminatory solution to hashish. These days marks a monumental action in remedying our federal hashish legislation. The Healthcare Cannabis and Cannabidiol Analysis Growth Act will make it much easier to examine the impacts and possible of hashish,” the statement reads.

Moreover, the Reps highlighted how fundamental is health care investigation on cannabis to realize the full medicinal probable of the plant to address a huge array of health care conditions and pledged to do the job on ending the war on medicines through a collection of approaching proposals that will reshape the standing of cannabis at the federal stage.

The legislation substantially eases the life of experts who want to research marijuana for health-related uses, as they experienced to observe strict laws that could delay their investigation.

The new laws removes federal restrictions in order to ease research from researching the plant and speeds up the software course of action to approve cannabis-relevant scientific experiments.

Less than the new law, the federal federal government has to make sure an adequate, uninterrupted provide of marijuana accessible to scientists for studies on clinical cannabis.

Thus, scientists will be equipped to master much more about the plant’s health care qualities and request big quantities of marijuana to use for analysis.

In actuality, the laws now demands that inside of 60 times of getting a researcher’s application, the U.S. Lawyer General has to approve it, request much more facts, or deny it specifying the good reasons. If scientists submit extra facts upon request, the Lawyer Common has 30 times to make a decision.

Universities and exploration establishments will now be able to obtain U.S. Drug Enforcement Administration (DEA) license to mature, manufacture, distribute, dispense and possess cannabis for investigate uses, with advice from the Section of Wellbeing and Human Solutions (HHS) and the U.S. Foodstuff And Drug Administration.

Scientists who want to do marijuana investigation may well update their protocol with no informing the DEA if the quantity and variety of cannabis, the resource, and the storage circumstances of the product would not modify.

The laws also encourages the Fda to produce cannabis-derived medications and addresses the HHS to determine the opportunity healthcare added benefits of cannabis or cannabidiol (or CBD) as a drug.

The Health care Cannabis and Cannabidiol Investigation Growth Act also intervenes in the medical doctor-affected individual marriage by letting medical professionals to talk about the at the moment acknowledged opportunity harms and gains of cannabis cannabinoids, these as CBD, as a therapy or the recognised achievable damages and rewards of cannabis and its compounds.

Even so, the legislation doesn’t allow for scientists to attain marijuana from point out-operate dispensaries and is not going to reschedule marijuana at the federal stage.

In actuality, marijuana will keep on being illegal at the federal stage below Agenda I of the Controlled Substances Act.

Nonetheless, the laws represents a important stage ahead for professional medical exploration on cannabis in the U.S.

Prior to the new law, undertaking investigate on marijuana was incredibly tough in the U.S. as researchers required approval from various organizations to perform scientific studies, which could often consider many years.

On top of that, experts were only allowed to use marijuana developed by the College of Mississippi, although the DEA has a short while ago awarded 6 other marijuana cultivation licenses for investigate to U.S. organizations.

Biden’s signature of The Medical Marijuana and Cannabidiol Investigate Expansion Act follows the executive order in Oct pardoning about 6,500 persons convicted for marijuana possession at the federal degree.

On that situation, he also requested the Secretary of the HHS and the Legal professional Typical to “initiate the approach of examining how marijuana is scheduled beneath federal legislation.”

Despite the fact that the new regulation doesn’t put into practice much more reform at the federal level, it might pave the way for new federal legislation on cannabis, these types of as the Risk-free Banking Act, that may simplicity the federal limitations on the cannabis industry.

Huntington Medical Research Institutes to Host Holiday Open House Commemorating 70th Anniversary

Milestone anniversary celebrates Pasadena-based organization’s huge contribution to transforming medicine and saving millions of lives

PASADENA, Calif., December 02, 2022–(BUSINESS WIRE)–Huntington Medical Research Institutes (HMRI), a leading biomedical research organization in Southern California, is celebrating its 70^th anniversary by opening its doors to the public this Saturday, December 3, 2022, from 11 a.m. to 3 p.m. for its Holiday Open House.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221202005288/en/

Huntington Medical Research Institutes to Host Holiday Open House Commemorating 70th Anniversary

HMRI 70th Anniversary Holiday Open House (Graphic: Business Wire)

The event is free to attend (registration requested) and offers:

Hands-on science activities for kids
Information on HMRI’s summer 2023 education programs for high school and college students
Talks with HMRI scientists on their latest discoveries about Alzheimer’s disease, mental illness, heart health, Covid-19 and more
Games, music, art and food trucks

“We’re celebrating 70 years of groundbreaking science and we are not done yet,” reflected Julia E. Bradsher, PhD, MBA, president and CEO of HMRI. “We have many more important discoveries in our future as we grow and continue to develop as a leading research institution. We look forward to celebrating many more innovative discoveries in our focus areas of cardiovascular, neurovascular and neuroscience research.”

HMRI began as an outgrowth of two separate institutes: Pasadena Foundation for Medical Research, established in 1952, and the Institute of Medical Research of Huntington Memorial Hospital, founded in 1953. The establishment of a third in 1961, the Neurovascular Research Foundation, formed a triumvirate in Pasadena. After a series of mergers over the course of three decades, in 1982, HMRI as we know it today was born.

For 70 years, the research facilities have generated a multitude of leading-edge innovations that have transformed the way people around the world protect their well-being and improve their health. Some of the noteworthy innovations from HMRI include:

Cerebrospinal fluid shunt valve system developed for hydrocephalus, “water on the brain.” The Pudenz valve system is still commonly used today.
Retractable seatbelts invented through study of preventing head traumas in car accidents in the 1950s.
Early research into prostate cancer cells, resulting in an immortalized cell line which is now widely used to test new prostate cancer drugs.
Demonstrating the diagnostic value of magnetic resonance imagining (MRI) in medical practice.
Perfecting magnetic resonance spectroscopy for diagnosing brain and heart conditions.

Currently, HMRI’s researchers are exploring new therapies and diagnostic methods that may transform the way we care for our hearts and brains.

HMRI’s mission is to advance scientific discovery through innovative biomedical research to improve health outcomes and inspire the next generation of scientists. “Within 10 years, we aim to become one of the leading biomedical research organizations in the United States,” stated Bradsher.

In addition to scientific discovery, HMRI has a long history of providing research opportunities for postdoctoral scientists and training undergraduate students in laboratory techniques.

“HMRI has welcomed postdoc and student researchers for years now,” explains Nicole Purcell, PhD, scientific director of education programs for HMRI. “We’re teaching research methods to students who are learning in a science lab for the very first time. We want HMRI to be recognized as a destination of choice for the next generation of scientists.”

Members of the media are invited to attend the holiday open house and speak with HMRI’s leading scientists about current research projects and how they see the world of medicine evolving as we approach 2023. Media may register here: https://bit.ly/HMRI70-Media.

Members of the public can register to attend the event here: https://hmri.org/70years/.

About HMRI

Huntington Medical Research Institutes (HMRI) is an independent, nonprofit organization located in Pasadena, California. Since its beginnings in 1952, HMRI research has led to the development of diagnostics, medical devices and therapies that improve the lives of millions of patients worldwide. HMRI conducts life-changing studies of the heart, the brain and the vascular intersection between the two. The institute’s scientists seek solutions to daunting cardiovascular and neurological challenges, like heart disease, Alzheimer’s disease, migraine and mental illness. For more information, visit HMRI.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221202005288/en/

Contacts

Media Contact
Audrey Chittick
mPR on behalf of HMRI
audrey@mpublicrelations.com

A Guide to Becoming a Clinical Research Nurse

Courtesy of Getty Images

Maybe you’re a nurse who would also like to be more involved in the clinical research process. Or maybe you’re a nurse who also wants to ensure the highest standard of care for patients in research trials.

If either of these things are true for you, then you might have what it takes to become a clinical research nurse.

Clinical research nurses are an integral part of the research process. They are essentially the managers of the most important part of any medical research: the trial patients themselves.

The role can be very rewarding, both mentally and financially. It’s not without its challenges, however, and that is something everyone who wants to be a clinical research nurse should take into account.

To help with this decision, BioSpace has outlined the role of a clinical research nurse, its ups and downs, and what it takes to become part of this crucial role.

What is a Clinical Research Nurse?

A clinical research nurse is responsible for the direct care of patients who are participants in clinical trials. These trials could involve anything from testing new treatments to researching novel approaches to human health.

The clinical research nurse is responsible for administering treatment, collecting data from test results and ensuring that the care, best interests and confidentiality of their patients are maintained at all times.

In this way, the role seems similar to that of a traditional nurse. There are a few key differences, however. The role of the clinical research nurse also involves:

Greater involvement in the research process. A clinical research nurse may be involved in designing the actual clinical trial. He or she may also be asked to help design patient protocols for future trials as well. The clinical research nurse may also be involved in the initial screening process for selecting patients for trials.

An understanding of how clinical research works. A clinical research nurse requires in-depth knowledge of the clinical research process itself. This means he or she must understand how trials are designed, how treatments are administered and how conclusions are drawn from the results.

Maintaining confidentiality of both the patient and the project. In addition to maintaining the confidentiality of their patients, the clinical research nurse must also maintain the confidentiality of the entire research project as well.

Clinical research nurses may work out of typical nursing settings, such as hospitals and long-term care facilities. However, they are just as likely to work out of biotech laboratories or university research centers. Depending on the type of study, their patients may be day patients or inpatients at various care centers.

Pros of Becoming a Clinical Research Nurse

It’s an integral role in developing better patient care. Clinical research nurses are involved with more than the care of their patients. They’re also helping to develop new treatments and better research that could one day help future patients. For this reason, clinical research nurses usually find their work very rewarding.

Compensation is competitive. Clinical research nurses often receive higher salaries than traditional nurses. While the median annual salary of a registered nurse in the US is $ 93,089, the median annual salary of a clinical research nurse is $116,2992.

The need for clinical research nurses will continue to grow. As the US population ages, the need for more medical research will increase. This means the need for more clinical research nurses will increase as well. Anyone with the qualifications to become a clinical research nurse should have no trouble finding work.

Cons of Becoming a Clinical Research Nurse

Patient advocacy may be a source of stress. In clinical research situations, the pressure may be on to ensure the research can be completed on time. In these cases, the clinical research nurse may need to step up and speak on behalf of their patients.

Drugs administered are not always FDA-approved. Because clinical research nurses work in clinical trials, many of the drugs they administer to patients may be experimental. Someone who is not comfortable with this may want to consider a different career.

Regardless of the impact on the study itself, the clinical research nurse’s patients must be their top priority. If patient advocacy is not a source of stress for you, then this should be of little to no issue.

Necessary Skills and Experience

The basic requirements of a clinical research nurse are similar to traditional nurses. A bachelor’s degree in nursing, biology or a similar discipline is required. Most job postings require a current state license as a registered nurse as well.

Many clinical research centers require at least some experience in a research setting. This can be gained by applying for roles as a clinical research assistant first. Once enough experience is gained in this type of role, nurses can apply for clinical research nursing positions.

Nurses may also want to consider earning a master’s of science in nursing in order to qualify for top-paying clinical research nursing positions.

Clinical research companies also look for several crucial soft skills. Good communication skills, the ability to be well-organized at all times and an innate sense of ethics are all important in a clinical nursing role.

Taking the Next Step

If you’re a caring and compassionate nurse who also has a strong desire to improve medical care for the future, then a role as a clinical research nurse may be the perfect fit for you.

If you’re ready to start applying, be sure to check out BioSpace’s current job postings for clinical research nurses.

Circuit Clinical and Middletown Medical Partner to Expand Access to Clinical Research for 100K+ Patients in the Hudson Valley

BUFFALO, N.Y., Nov. 29, 2022 /PRNewswire/ — Circuit Clinical—one of the nation’s fastest growing integrated research organizations—has expanded their presence in the Hudson Valley region through a partnership with Middletown Medical, a top tier, multi-specialty physician group, increasing access to clinical research as a care option to an additional 100,000 patients that Middletown Medical serves. This partnership will bring trials to a more diverse patient population—comprised of approximately 50{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} non-white individuals.